X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CMP-CPS-001 is an antisense oligonucleotide (ASO) designed to amplify CPS1 mRNA by harnessing fundamental cellular gene expression control mechanisms. It is being evaluated for the treatment of urea cycle disorders.
Lead Product(s): CMP-CPS-001
Therapeutic Area: Genetic Disease Product Name: CMP-CPS-001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Fulcrum gains worldwide license to intellectual property arising from CAMP4’s DBA program, including the rights for discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fulcrum Therapeutics
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Details:
The financing round will further support the advancement of CAMP4’s drug candidates, including progressing its urea cycle disorder program into the clinic and continuing to build an expansive pipeline of RNA actuators.
Lead Product(s): Antisense Oligonucleotide Therapeutic
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Patient Square Capital
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 20, 2022
Details:
CAMP4 is pioneering a novel approach to programmable therapeutics that combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: OPKO Health
Deal Size: $93.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2021
Details:
Proceeds to fuel expansion of RNA Actuating Platform™ designed to harness the power of regulatory RNA to restore healthy gene expression. Company advancing preclinical pipeline initially focused on CNS and liver diseases; first IND expected in 2022.
Lead Product(s): regRNAs Therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
